Solixia is an early stage biotechnology company dedicated to helping cancer patients.

The Company's product candidates are based on proprietary HotDot™ nanoparticle technology and will have at least ten times the radioactive payload as existing radiopharmaceuticals. HotDot™ nanoparticles can be attached to molecules for the purpose of tumor targeting, making them capable of avoiding healthy cells. They are useful for both diagnostic and therapeutic applications.

Solixia's lead compound, SLX-1016, is a breast cancer imaging agent in preclinical development.